Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


Trevi Therapeutics
52 Charter Ridge Road
New Haven, CT 6482
Phone: 203-304-2499
www.trevitherapeutics.com

Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions. The Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. T111 is an oral extended release opioid with a unique dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus.

Key Contact
NameTitleE-Mail
Jennifer GoodCEO


Funding Events
DateAmountTypeInvestors
12/18/12$10,000,000Series A TPG Biotech
06/04/14$25,000,000Series B TPG Biotech
07/20/17$50,500,000Series C Aperture Venture Partners
Lundbeckfonden Ventures
New Enterprise Associates  
Omega Funds
TPG Biotech
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.